难治性抑郁症
奎硫平
萧条(经济学)
鼻喷雾剂
医学
随机对照试验
安慰剂
内科学
麻醉
心理学
精神科
抗抑郁药
药理学
替代医学
鼻腔给药
精神分裂症(面向对象编程)
宏观经济学
病理
海马体
经济
作者
Joshua D. Rosenblat,Roger S. McIntyre
出处
期刊:Med
[Elsevier]
日期:2023-12-01
卷期号:4 (12): 852-854
被引量:2
标识
DOI:10.1016/j.medj.2023.11.002
摘要
While new add-on treatments have been developed for augmentation in depression with benefits demonstrated compared to placebo, none have demonstrated superiority compared to previously available interventions until now. In a phase IIIb, randomized, active-controlled trial (ESCAPE-TRD), Reif et al. 1 Reif A. Bitter I. Buyze J. Cebulla K. Frey R. Fu D.-J. Ito T. Kambarov Y. Llorca P.-M. Oliveira-Maia A.J. et al. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. N. Engl. J. Med. 2023; 389: 1298-1309 Crossref Scopus (4) Google Scholar demonstrate the superiority of esketamine compared to quetiapine augmentation (the current standard-of-care).
科研通智能强力驱动
Strongly Powered by AbleSci AI